Impact of Statins and ACE Inhibitors on Mortality After COPD Exacerbations

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2009 Jun 5

PMID 19493329

Citations 56

Authors

Eric M Mortensen

Laurel A Copeland

Mary Jo V Pugh

Marcos I Restrepo

Rosa Malo de Molina

Brandy Nakashima

Antonio Anzueto

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of our study was to examine the association of prior outpatient use of statins and angiotensin converting enzyme (ACE) inhibitors on mortality for subjects >or= 65 years of age hospitalized with acute COPD exacerbations.

Methods: We conducted a retrospective national cohort study using Veterans Affairs administrative data including subjects >or=65 years of age hospitalized with a COPD exacerbation. Our primary analysis was a multilevel model with the dependent variable of 90-day mortality and hospital as a random effect, controlling for preexisting comorbid conditions, demographics, and other medications prescribed.

Results: We identified 11,212 subjects with a mean age of 74.0 years, 98% were male, and 12.4% of subjects died within 90-days of hospital presentation. In this cohort, 20.3% of subjects were using statins, 32.0% were using ACE inhibitors or angiotensin II receptor blockers (ARB). After adjusting for potential confounders, current statin use (odds ratio 0.51, 95% confidence interval 0.40-0.64) and ACE inhibitor/ARB use (0.55, 0.46-0.66) were significantly associated with decreased 90-day mortality.

Conclusion: Use of statins and ACE inhibitors prior to admission is associated with decreased mortality in subjects hospitalized with a COPD exacerbation. Randomized controlled trials are needed to examine whether the use of these medications are protective for those patients with COPD exacerbations.

Citing Articles

Proteomic networks and related genetic variants associated with smoking and chronic obstructive pulmonary disease.

Konigsberg I, Vu T, Liu W, Litkowski E, Pratte K, Vargas L BMC Genomics. 2024; 25(1):825.

PMID: 39223457 PMC: 11370252. DOI: 10.1186/s12864-024-10619-1.

The impact on thirty day readmissions for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease admitted to an observation unit versus an inpatient medical unit: A retrospective observational study.

Bell J, Lim S, Mikami T, Bahk J, Argiro S, Steiger D Chron Respir Dis. 2024; 21:14799731241242490.

PMID: 38545901 PMC: 10981268. DOI: 10.1177/14799731241242490.

A Literature Review on the Coexisting Chronic Obstructive Pulmonary Disease and Heart Failure.

Tasha T, Desai A, Bajgain A, Ali A, Dutta C, Pasha K Cureus. 2023; 15(10):e47895.

PMID: 38034213 PMC: 10682741. DOI: 10.7759/cureus.47895.

Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities.

Matera M, Hanania N, Maniscalco M, Cazzola M Drugs Aging. 2023; 40(7):605-619.

PMID: 37316689 PMC: 10300166. DOI: 10.1007/s40266-023-01038-0.

Renin-angiotensin-system inhibitors and the risk of exacerbations in chronic obstructive pulmonary disease: a nationwide registry study.

Vilstrup F, Heerfordt C, Kamstrup P, Hedsund C, Biering-Sorensen T, Sorensen R BMJ Open Respir Res. 2023; 10(1).

PMID: 36882221 PMC: 10008458. DOI: 10.1136/bmjresp-2022-001428.

References

Jialal I, Stein D, Balis D, Grundy S, Adams-Huet B, Devaraj S . Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001; 103(15):1933-5. DOI: 10.1161/01.cir.103.15.1933. View

Lee T, Bartle B, Weiss K . Spirometry use in clinical practice following diagnosis of COPD. Chest. 2006; 129(6):1509-15. DOI: 10.1378/chest.129.6.1509. View

Pauwels R, Buist A, Ma P, Jenkins C, Hurd S . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive.... Respir Care. 2001; 46(8):798-825. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Grijalva C, Arbogast P, Griffin M . Statins and influenza/COPD mortality. Chest. 2007; 132(4):1407. DOI: 10.1378/chest.07-0952. View

Mancini G, Etminan M, Zhang B, Levesque L, FitzGerald J, Brophy J . Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006; 47(12):2554-60. DOI: 10.1016/j.jacc.2006.04.039. View

Joo M, Lee T, Weiss K . Geographic variation in chronic obstructive pulmonary disease exacerbation rates. J Gen Intern Med. 2007; 22(11):1560-5. PMC: 2219808. DOI: 10.1007/s11606-007-0354-6. View

Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R . Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol. 1999; 34(7):2061-7. DOI: 10.1016/s0735-1097(99)00495-7. View

Yoshida T, Tuder R . Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev. 2007; 87(3):1047-82. DOI: 10.1152/physrev.00048.2006. View

10.

Fedson D . Statin protection against influenza and COPD mortality. Chest. 2007; 132(4):1406. DOI: 10.1378/chest.07-0992. View

11.

Cowper D, Kubal J, Maynard C, Hynes D . A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002; 12(7):462-8. DOI: 10.1016/s1047-2797(01)00285-x. View

12.

Suissa S . Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2007; 167(4):492-9. DOI: 10.1093/aje/kwm324. View

13.

Frost F, Petersen H, Tollestrup K, Skipper B . Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007; 131(4):1006-12. DOI: 10.1378/chest.06-1997. View

14.

Stockley R . Lung infections. 1. Role of bacteria in the pathogenesis and progression of acute and chronic lung infection. Thorax. 1998; 53(1):58-62. PMC: 1758695. DOI: 10.1136/thx.53.1.58. View

15.

Yende S, Tuomanen E, Wunderink R, Kanaya A, Newman A, Harris T . Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med. 2005; 172(11):1440-6. PMC: 2718438. DOI: 10.1164/rccm.200506-888OC. View

16.

Soyseth V, Brekke P, Smith P, Omland T . Statin use is associated with reduced mortality in COPD. Eur Respir J. 2006; 29(2):279-83. DOI: 10.1183/09031936.00106406. View

17.

Sethi S, Muscarella K, Evans N, Klingman K, Grant B, Murphy T . Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest. 2000; 118(6):1557-65. DOI: 10.1378/chest.118.6.1557. View

18.

Selim A, Berlowitz D, Fincke G, Cong Z, Rogers W, Haffer S . The health status of elderly veteran enrollees in the Veterans Health Administration. J Am Geriatr Soc. 2004; 52(8):1271-6. DOI: 10.1111/j.1532-5415.2004.52355.x. View

19.

Claxton A, Cramer J, Pierce C . A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23(8):1296-310. DOI: 10.1016/s0149-2918(01)80109-0. View

20.

Schneeweiss S, Seeger J, Maclure M, Wang P, Avorn J, Glynn R . Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001; 154(9):854-64. DOI: 10.1093/aje/154.9.854. View